Search
Seer Inc
SEERAdd to Watchlist
1.660USD
-0.070-4.05%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
91.27MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-4.05%
5 Days
-4.60%
1 Month
-13.99%
6 Months
-9.78%
Year to Date
-9.29%
1 Year
-21.70%
Key Figures
1.720Open
1.757High
438.86KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.80%Turnover Ratio
1.730Prev. Close
1.660Low
561.77KTurnover
LossP/E Static
0.38P/B
0.00%Div Yield TTM
-22.76%ROA
2.41052wk High
2.37Volume Ratio
-86.60MNet Profit
55.07MShares
-1.2461EPS TTM
1.61Beta
-25.52%ROE
1.65052wk Low
5.62%Amplitude
35.16%Gross Margin
91.27MMarket Cap
-3.31Reward/Risk
2.26%Risk Rate
TradingKey Stock Score of Seer Inc
Currency: USD Updated: 2026-06-26Key Insights
Seer Inc's fundamentals are relatively very healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 6 out of 7 in the Office Equipment industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Seer Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative-
Seer Inc Highlights
StrengthsRisks
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.58M.
Fairly Valued
The company’s latest PB is 0.38, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 29.42M shares, decreasing 20.92% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 13.17K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.45.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
4.000
Target Price
+140.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Seer Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Seer Inc Info
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Ticker SymbolSEER
CompanySeer Inc
CEOFarokhzad (Omid C)
Websitehttps://seer.bio/
Related Instruments
-1.64%
+3.14%
-0.61%
-3.67%
-6.69%
-2.06%
-2.53%
-3.42%
-6.16%
-5.66%
-4.37%
-3.87%
-3.93%
-10.46%
-8.46%
-3.73%
-5.15%
-12.24%
-13.17%
-1.01%Popular Instruments
52006.900
+254.700 (+0.49%)
29395.600
+408.100 (+1.41%)
7394.400
+62.400 (+0.85%)
15384.000
+102.000 (+0.67%)
69812.000
+304.000 (+0.44%)
6214.600
+7.500 (+0.12%)
69.926
-0.222 (-0.32%)
283.780
+8.630 (+3.14%)
192.530
-3.210 (-1.64%)
4033.160
-54.600 (-1.34%)
FAQs
What is the current price of Seer Inc (SEER)?
The current price of Seer Inc (SEER) is 1.66.
What is the symbol of Seer Inc?
The ticker symbol of Seer Inc is SEER.
What is the 52-week high of Seer Inc?
The 52-week high of Seer Inc is 2.41.
What is the 52-week low of Seer Inc?
The 52-week low of Seer Inc is 1.65.
What is the market capitalization of Seer Inc?
The market capitalization of Seer Inc is 91.41M.
Is Seer Inc (SEER) currently rated as Buy, Hold, or Sell?
According to analysts, Seer Inc (SEER) has an overall rating of Buy, with a price target of 4.00.
What is the Earnings Per Share (EPS TTM) of Seer Inc (SEER)?
The Earnings Per Share (EPS TTM) of Seer Inc (SEER) is -1.28.
